Seelos Therapeutics, Inc.’s Phase II study of SLS-002 (intranasal racemic ketamine) in acute suicidal ideation and behavior (ASIB) among adults with major depressive disorder (MDD) fell short of its primary endpoint because the company did not have enough funding to fully enroll it, but the company remains confident that it has sufficiently de-risked the drug.
Seelos said 20 September that data from the trial demonstrated clinically meaningful treatment effects across multiple endpoints and a well-tolerated...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?